Last updated: July 28, 2026
Genzyme Corp. v. Zenara Pharma Private Limited (1:19-cv-00264) Litigation Summary, Patent Issues, and Case Posture
Genzyme Corp. v. Zenara Pharma Private Limited, Case No. 1:19-cv-00264 (filed 2019), is a federal patent infringement action. The docket number indicates a District Court case in the First Circuit’s default civil numbering scheme for that year, but the specific asserted patents, claims, pleadings content, and current procedural posture (dismissal, settlement, trial, or status) are not provided in the input. Without the docket’s substantive record (complaint/patent list, amended pleadings, Markman orders, claim construction, dispositive rulings, and final judgment), a complete litigation summary and enforceable patent/legal analysis cannot be produced.
What patents were asserted in Genzyme Corp. v. Zenara Pharma Private Limited (1:19-cv-00264)?
Answer: Not specified in the provided information.
Which patent numbers and expiration dates drove the case?
Answer: Not specified in the provided information.
Were Orange Book (Hatch-Waxman) Orange Book listings involved?
Answer: Not specified in the provided information.
What infringement theories were alleged (product, method, formulation, use)?
Answer: Not specified in the provided information.
What is the litigation posture for 1:19-cv-00264 (motions, hearings, trial, or settlement)?
Answer: Not specified in the provided information.
What did the court decide on any dispositive motions?
Answer: Not specified in the provided information.
Was there a claim construction (Markman) order?
Answer: Not specified in the provided information.
Did the parties settle, dismiss, or proceed to judgment?
Answer: Not specified in the provided information.
Was this case tied to FDA approval, Paragraph IV, or biosimilar pathways?
Answer: Not specified in the provided information.
If Hatch-Waxman: what was the Abbreviated New Drug Application (ANDA) status?
Answer: Not specified in the provided information.
If biologics/biosimilars: what was the BLA/351(k) status?
Answer: Not specified in the provided information.
How strong is Genzyme’s patent estate in this dispute based on the docket record?
Answer: Not specified in the provided information.
How many patents were asserted and which are core composition vs. secondary method/formulation?
Answer: Not specified in the provided information.
What claim coverage risks existed (design-around, non-infringement, indefiniteness, obviousness)?
Answer: Not specified in the provided information.
What defenses did Zenara raise in the infringement case?
Answer: Not specified in the provided information.
What validity challenges were pled (35 USC 101/102/103/112)?
Answer: Not specified in the provided information.
What non-infringement positions were taken (scope, equivalents, literal infringement)?
Answer: Not specified in the provided information.
Did Genzyme obtain any remedies (injunction, damages, enhanced damages, attorneys’ fees)?
Answer: Not specified in the provided information.
What was the final judgment or current status of relief?
Answer: Not specified in the provided information.
Key Takeaways
- The docket identifier 1:19-cv-00264 is confirmed only as a case number, but the asserted patents, pleadings, procedural milestones, and outcome are not included in the provided input.
- A litigation summary and patent/legal analysis that is accurate and decision-useful requires the complaint’s asserted patent list and allegations plus subsequent docket events.
FAQs
- What is the asserted patent list in Genzyme Corp. v. Zenara Pharma Private Limited (1:19-cv-00264)?
- What claims were construed in Genzyme v. Zenara and how did that affect infringement analysis?
- Was the case resolved via settlement or did it reach judgment?
- Did Zenara challenge patent validity on 35 USC 101, 102, 103, or 112 grounds?
- Was any FDA regulatory action tied to the alleged infringement in this case?
References
- None provided in the input.
